Symetis and Boston Scientific Reach USD 435 Million Purchase Agreement

PR68012

ECUBLENS, Switzerland, March 30, 2017 / PRNewswire=KYODO JBN /

     - Definitive purchase agreement whereby Boston Scientific will acquire

Symetis for $435 million in an all cash, up-front payment

     - Acquisition of Symetis will expand the treatment offerings for patients

with aortic valvular heart disease

     - Acquisition projected to close during the second quarter of 2017,

subject to customary closing conditions

     - Symetis' IPO launched on Euronext Paris and very well received by the

investment community, has been halted

     Symetis, a medical technology company specializing in the development,

manufacturing and marketing of percutaneous heart valve replacement solutions

for the treatment of severe cardiac valve conditions, today announced that it

has agreed to be acquired by Boston Scientific for $435 million in an all cash,

up-front payment.

     (Logo: http://mma.prnewswire.com/media/484319/Symetis_Logo.jpg )

     (Photo:

http://mma.prnewswire.com/media/484320/Symetis_Acurate_Neo_Valve.jpg )

     The acquisition of Symetis by Boston Scientific will allow the company to

extend its reach and expand the treatment offerings for patients with aortic

valvular heart disease worldwide. The combination of Symetis' ACURATE valves

with the Boston Scientific Lotus(TM) valve platform, will also enable

interventional cardiologists and cardiac surgeons to address varying patient

pathologies and anatomies with two complementary and compelling technologies.

     Jacques R. Essinger, Ph.D. and CEO, Symetis, commented "Over the past

years, Symetis matured into a TAVI (Transcatheter Aortic Valve Implantation)

player with fast growth and a solid clinical reputation. The IPO that we were

pursuing until yesterday on Euronext Paris was meant to give Symetis the means

to commercially expand beyond Europe and to further grow into the exciting

field of structural heart. We are very pleased by the positive response we

received from the investment community, which we want to thank for the interest

it has shown in Symetis. However, as of today, the company is taking another

path by joining Boston Scientific. The global scale and strong legacy of Boston

Scientific in interventional cardiology will further propel Symetis' clinical

excellence. As a result, we can expect more patients to be better treated for

valvular heart disease globally. Moving forward, this means an exciting

development path for the Symetis team."

     Dominik Ellenrieder, Symetis' Chairman, added "Growing at a strong and

sustained CAGR of 55% since 2012, Symetis is a success story in the structural

heart market. This purchase agreement is a recognition of Symetis' research and

development track record in addressing patients' needs with innovative

structural heart technologies, the company's manufacturing expertise and its

strong relationships with doctors and healthcare professionals. We are excited

about the strong potential of our combined strengths to set a new standard in

the TAVI market with a broad and clinically differentiated offering."

     Following the purchase agreement reached with Boston Scientific, the IPO

launched on 20 March 2017 by Symetis on Euronext Paris, very well received by

the investment community and which was originally expected to be completed on

31 March 2017, has been halted. The acquisition of Symetis by Boston Scientific

is projected to close during the second quarter of 2017, subject to customary

closing conditions.

     About Symetis

     Symetis, founded in 2001, is a medical technology company specializing in

the development, manufacturing and marketing of percutaneous heart valve

replacement solutions for the treatment of severe cardiac valve conditions.

     Symetis' products, ACURATE TA(TM) and ACURATE neo/TF, and their delivery

systems are based on proprietary design and delivery technologies and are

marketed and sold in key markets in Europe and in other geographies. Symetis'

innovative TAVI solutions are recognized by intervention cardiologists and

surgeons for their clinical performance and ease of use.

     Growing at a strong and sustained CAGR of 55% since 2012, the company

generated revenues of CHF 38.4 million in 2016.

     Symetis is a Swiss company with corporate headquarters in Ecublens,

Switzerland and its products are produced in Switzerland and Brazil.

     For more information visit http://www.symetis.com

     Symetis

     Khaled Bahi - Chief Financial Officer

     +41(0)-21-651-01-60

     investors@symetis.com    

     Weber Shandwick

     Alphonse Daudre-Vignier

     +41-(0)-79-127-63-58

     adaudre-vignier@webershandwick.com

Source: SYMETIS SA